KR900009624A - 황-함유 헤테로 고리 화합물 - Google Patents

황-함유 헤테로 고리 화합물 Download PDF

Info

Publication number
KR900009624A
KR900009624A KR1019890019906A KR890019906A KR900009624A KR 900009624 A KR900009624 A KR 900009624A KR 1019890019906 A KR1019890019906 A KR 1019890019906A KR 890019906 A KR890019906 A KR 890019906A KR 900009624 A KR900009624 A KR 900009624A
Authority
KR
South Korea
Prior art keywords
group
compound
substitutable
hydrogen atom
ring
Prior art date
Application number
KR1019890019906A
Other languages
English (en)
Other versions
KR0142429B1 (ko
Inventor
다까시 소오다
쓰다마사오
이와요 야마자끼
Original Assignee
우메모또 요시마사
다께다야꾸힝 고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다야꾸힝 고오교 가부시끼가이샤 filed Critical 우메모또 요시마사
Publication of KR900009624A publication Critical patent/KR900009624A/ko
Application granted granted Critical
Publication of KR0142429B1 publication Critical patent/KR0142429B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06Benzothiopyrans; Hydrogenated benzothiopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D337/00Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02Seven-membered rings
    • C07D337/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4021Esters of aromatic acids (P-C aromatic linkage)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056Esters of arylalkanephosphonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655363Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
    • C07F9/655372Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655381Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring
    • C07F9/65539Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Lubricants (AREA)
  • Pretreatment Of Seeds And Plants (AREA)

Abstract

내용 없음

Description

황-함유 헤테로 고리 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 식(Ⅰ)의 황-함유 헤테로 고리 화합물 또는 약학적으로 허용 가능한 그의 염36-1
    [상기식에서, 고리 A는 치환 가능한 벤젠고리이며, R은 수소 원자 또는 치환 가능한 탄화수소기이고, B는 에스테르화 또는 아미드화 가능한 카르복실기이며, X는 -CH(OH)- 또는 -CO-이고, k는 0 또는 1이며, k'은 0. 1 또는 2이다]
  2. 제1항에 있어서, 고리 A가 할로겐, C1~10 알킬 및 C1~6알콕시로 구성된 군으로 부터 선택된, 동일하거나 상이한. 1 또는 2개의 치환체에 의해 치환 가능한 벤젠고리인 화합물.
  3. 제1항에 있어서, 고리 A가 동일하거나 상이한, 1 또는 2개의 C1~10알킬기에 의해 치환가능한 벤젠 고리인 화합물.
  4. 제1항에 있어서, 고리 A가 C3~7시클로알킬기에 의해 치환가능한 벤젠고리인 화합물.
  5. 제1항에 있어서, R이 수소원자, C1~10알킬 또는 페닐기인 화합물.
  6. 제1항에 있어서, R이 수소원자 또는 메틸기인 화합물.
  7. 제1항에 있어서, B가 C1~10알콕시카르보닐기 또는 식 -CONR1R2의 기(식중, R1및 R2각각은 수소원자,치환가능한 탄화수소기 또는 치환가능한 5- 내지 7-원소로 된 헤테로고리기이다.)인 화합물.
  8. 제1항에 있어서, B가 식 -CONR1R2의 기(식중, R1및 R2각각은 수소원자, 치환가능한 탄화수소기 또는 치환가능한 5- 내지 7-원소로된 헤테로고리기 이다.)인 화합물.
  9. 제8항에 있어서, R1이 수소원자이며 R2가 식 -C6H5(CH2)nP(0)(OR')2의 기(식중, n은 0 또는 1이며 R'은 C1~6알킬기 이다.)인 화합물.
  10. 제1항에 있어서, 고리 A가 할로겐, C1~10알킬 및 C1~6알콕시로 구성된 군으로 부터 선택된, 동일하거나 상이한, 1 또는 2개의 치환체에 의해 치환 가능한 벤젠고리이며, R은 수소원자, C1~10알킬 또는 페닐기이며, B는 C1~10 알콕시카르보닐기 또는 식 -CONR1R2의 기(식중, R1및 R2각각은 수소원자, 치환가능한 탄화수소기 또는 치환가능한 5- 내지 7-원소로된 헤테로 고리기 이다.)이고, k 및 k'은 각각 0인 화합물.
  11. 제1항에 있어서, 6-시클로헥실-N-(4-디에톡시포스포릴메틸페닐)-3,4-디히드로-1H-2-벤조티오피란-4-온-1-카르복사미드라고 명명되는 화합물.
  12. 제1항에 있어서, 6,7-디멜틸-N-(4-디에톡시포스포릴페닐)-3,4-디히도로-1H-2-벤조티오피란-4-온-1-키르복사미드라고 명명되는 화합물.
  13. 제1항에 있어서, 6,7-디메틸-N-(4-디에톡시포스포릴메틸페닐)-3,4-디히드로- 1H-2-벤조티오피란-4-온-1-카르복사미드라고 명명되는 화합물.
  14. (1)하기 일반식(Ⅱ)의 화합물 또는 그의 염을 고리화 반응시키고, 필요한 경우, 산화 또는/및 가수분해, 가수분해후 아미드화, 또는 가수분해후 아미드화 및 산화반응을 더 수행하여 하기 일반식(Ⅰa)의 황-함유 헤테로고리 화합물 또는 그의 염을 제조하거나, 또는 (2)하기 일반식(Ⅰa)의 화합물 또는 그의 염을 환원시켜 하기 일반식(Ⅰb)의 황-함유 헤테로고리 화합물 또는 그의 염을 제조함을 특징으로 하는 하기 일반식(Ⅰ)의 황-함유 헤테로고리 화합물 또는 그의 염의 제조방법
    [상기식에서, B'은 에스테르화 카르복실기이며, B는 에스테르화 또는 아미드화 가능한 카르복실기이고, Y는 히도록시기 또는 할로겐 원자이며, X는 -CH(OH)- 또는 -CO-이고, 고리 A는 치환 가능한 벤젠고리이며, R은 수소원자 또는 치환가능한 탄화수소기이고, k는 0 또는 1이며, k'은 0.1 또는 2이다.]
  15. 유효량의 하기 일반식(Ⅰ)의 항-골다공성 화합물 또는 약학적으로 허용 가능한 염 및 약학적으로 허용가능한 담체 또는 희석제를 함유하는, 골다공증 치료에 사용하는 약학제제.
    [상기식에서, 고리 A는 치환 가능한 벤젠 고리이며, R은 수소원자 또는 치환 가능한 탄화수소기이고, B는 에스테르화 또는 아미드화 가능한 카르복실기이며, X는 -CH(OH)- 또는 -CO-이고, k는 0 또는 1이며, k'은 0.1 또는 2이다.]
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890019906A 1988-12-28 1989-12-28 황-함유 헤테로고리화합물 KR0142429B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP33524088 1988-12-28
JP88-335240 1988-12-28
JP89-303603 1989-11-21
JP30360389 1989-11-21

Publications (2)

Publication Number Publication Date
KR900009624A true KR900009624A (ko) 1990-07-05
KR0142429B1 KR0142429B1 (ko) 1998-06-01

Family

ID=26563567

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890019906A KR0142429B1 (ko) 1988-12-28 1989-12-28 황-함유 헤테로고리화합물

Country Status (16)

Country Link
US (1) US5071841A (ko)
EP (1) EP0376197B1 (ko)
JP (1) JP2924033B2 (ko)
KR (1) KR0142429B1 (ko)
CN (1) CN1032470C (ko)
AT (1) ATE112770T1 (ko)
AU (1) AU623722B2 (ko)
CA (1) CA2006723C (ko)
DE (1) DE68918827T2 (ko)
DK (1) DK656789A (ko)
ES (1) ES2060735T3 (ko)
FI (1) FI102896B1 (ko)
HK (1) HK17396A (ko)
HU (1) HU209453B (ko)
NO (1) NO179977C (ko)
NZ (1) NZ231939A (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158943A (en) * 1988-11-21 1992-10-27 Takeda Chemical Industries, Ltd. Sulfur-containing heterocyclic compounds
EP0460488B1 (en) * 1990-05-30 2001-07-11 Takeda Chemical Industries, Ltd. Sulfur-containing heterocyclic compounds
EP0769015B1 (en) * 1994-07-04 2001-03-14 Takeda Chemical Industries, Ltd. Phosphonic acid compounds, their production and use
TW403757B (en) 1994-12-28 2000-09-01 Takeda Chemical Industries Ltd Optically active benzothiepin derivative, its preparation and use
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
CA2226317A1 (en) * 1995-07-24 1997-02-06 Takeda Chemical Industries, Ltd. Production of optically active benzothiepin salts
ID18079A (id) 1996-08-26 1998-02-26 Takeda Chemical Industries Ltd Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
CA2267930A1 (en) * 1996-10-09 1998-04-16 Nobuyuki Takechi A method for producing a microparticle
CA2287228A1 (en) 1997-04-24 1998-10-29 Tetsuo Hoshino Apatite-coated solid composition
CA2334815A1 (en) * 1998-06-15 1999-12-23 Haruhiko Makino Composition for treating cartilage disease
US6355672B1 (en) 1998-08-07 2002-03-12 Takeda Chemical Industries, Ltd. Benzothiepin derivatives, process for the preparation of the same and uses thereof
TW557298B (en) * 2000-08-14 2003-10-11 Ciba Sc Holding Ag A compound, a photopolymerizible composition, a process for producing coatings and a method for causing a photoinitiator to accumulate at the surface of coatings
EP1324994A4 (en) * 2000-10-10 2004-06-16 Calyx Therapeutics Inc TRICYCLIC COMPOUNDS AND USES THEREOF
CA2637194A1 (en) 2006-01-18 2007-07-26 National University Corporation Tokyo Medical And Dental University Biomaterial for osteogenesis containing osteogenesis promoter and nanogel
KR101613745B1 (ko) 2008-02-29 2016-04-19 닛산 가가쿠 고교 가부시키 가이샤 티오펜 화합물 및 그 중간체의 제조 방법
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
ES2864277T3 (es) 2014-09-26 2021-10-13 Daiichi Sankyo Co Ltd Sal de compuestos de ácido dicarboxílico

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1935685A1 (de) * 1969-07-10 1971-01-14 Schering Ag Neue antimikrobiell wirksame Verbindungen
US3636049A (en) * 1969-11-26 1972-01-18 Pfizer Isothiochroman carboxamides
FR2621038B1 (fr) * 1987-09-28 1989-12-29 Rhone Poulenc Sante Derives d'alcadienes, leurs preparations, les medicaments les contenant et produits intermediaires

Also Published As

Publication number Publication date
FI102896B (fi) 1999-03-15
DE68918827D1 (de) 1994-11-17
ES2060735T3 (es) 1994-12-01
EP0376197B1 (en) 1994-10-12
CN1045106A (zh) 1990-09-05
ATE112770T1 (de) 1994-10-15
FI102896B1 (fi) 1999-03-15
CN1032470C (zh) 1996-08-07
HU896790D0 (en) 1990-03-28
FI896289A0 (fi) 1989-12-27
AU623722B2 (en) 1992-05-21
DK656789A (da) 1990-06-29
CA2006723A1 (en) 1990-06-28
DK656789D0 (da) 1989-12-21
HK17396A (en) 1996-02-09
AU4732089A (en) 1990-07-19
NZ231939A (en) 1991-07-26
DE68918827T2 (de) 1995-02-16
NO895267D0 (no) 1989-12-27
NO895267L (no) 1990-06-29
JP2924033B2 (ja) 1999-07-26
CA2006723C (en) 1998-08-25
NO179977C (no) 1997-01-22
KR0142429B1 (ko) 1998-06-01
US5071841A (en) 1991-12-10
EP0376197A1 (en) 1990-07-04
NO179977B (no) 1996-10-14
JPH03232880A (ja) 1991-10-16
HU209453B (en) 1994-06-28

Similar Documents

Publication Publication Date Title
KR900009624A (ko) 황-함유 헤테로 고리 화합물
MY129970A (en) Hypolipidaemic compounds
KR880001583A (ko) 광학적 활성 벤젠설폰아미드 유도체의 제조방법
ES2000604A6 (es) Un procedimiento para preparar aril-piperidin esteres
DE3767351D1 (de) Sialosylceramide und verfahren zu deren herstellung.
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
DE69324854D1 (de) Pyridazinone-Derivate und Verfahren zur deren Herstellung
CA2261098A1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR880005138A (ko) 신규 화합물들
HRP20000027B1 (en) Process for the preparation of alkoxyfuranoneamine derivatives, compounds obtained by this process, and the use of these compounds
FI93455B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1-oksa-2-okso-8-atsaspiro/4,5/dekaanijohdannaisten valmistamiseksi
DK141282A (da) Fremgangsmaade til fremstilling af morpholiner
KR960700252A (ko) 퀴놀린카르복실산 유도체 및 이의 제조방법(quinolinecarboxylic acid derivative and process for producing the same)
ATE122683T1 (de) Epoxybernsteinsäurederivate, verwendbar als spezifische hemmer von cathepsin b.
SE8406046D0 (sv) New azabiocyclic compounds and a process for the preparation thereof
DE60000375D1 (de) Verfahren zur Herstellung von Difluoracetophenon-Derivaten
DE68926016D1 (de) Halogeno-4-Methylpyrazole und Verfahren zu ihrer Herstellung
DK54180A (da) Fremgangsmaade til fremstilling af xanthonderivater
ATE90101T1 (de) Verfahren zur herstellung von makrolid-derivaten.
DK0455899T3 (da) Prostaglandin I-analog
AU5977980A (en) Aminodeoxyclavulanic acids

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020320

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee